Burles Avner Johnson

5PUBLICATIONS
48CO-AUTHORS
Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 13, 2026
Real-World Tumor-Informed Circulating Tumor DNA Dynamics and Survival Associations in Advanced Urothelial Cancer Treated With First-Line Enfortumab Vedotin and Pembrolizumab.

|Jan 07, 2026
Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma.

Akhilesh Mishra, Ajay Kumar Sharma, Kuldeep Gupta

|Oct 27, 2025
Intratumoral Expression of a Composite B Cell / CD8 T Cell Biomarker Stratifies Overall Survival by Circulating Tumor DNA Status and Benefit From Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Carcinoma.

Roy Elias, Adam K Aragaki, Jean H Hoffman-Censits

|Sep 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.

Howard L Li, Soren Charmsaz, Mari Nakazawa

|Aug 19, 2025
Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin-Related Dermatologic Events in Patients with Advanced Urothelial Cancer.

Evangelia Vlachou, Burles A Johnson, David J McConkey

Pageof 1

Frequent Collaborators

4 joint publications

Jean Hoffman-Censits

2 joint publications

Noah M Hahn

1 joint publications

Howard L Li

1 joint publications

Soren Charmsaz